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Community-acquired pneumonia (CAP) often results in 
severe illness and death. In large, geographically deﬁ  ned 
areas where Coccidioides spp. are endemic, coccidioidomy-
cosis is a recognized cause of CAP, but its frequency has 
not been studied extensively. To determine the frequency 
of patients with coccidioidomycosis, we conducted a pro-
spective evaluation of 59 patients with CAP in the Phoenix, 
Arizona, area. Of 35 for whom paired coccidioidal serologic 
testing was performed, 6 (17%) had evidence of acute coc-
cidioidomycosis. Coccidioidal pneumonia was more likely 
than noncoccidioidal CAP to produce rash. The following 
were not found to be risk factors or reliable predictors of 
infection: demographic features, underlying medical con-
ditions, duration of time spent in disease-endemic areas, 
occupational and recreational activities, initial laboratory 
studies, and chest radiography ﬁ  ndings. Coccidioidomyco-
sis is a common cause of CAP in our patient population. In 
the absence of distinguishing clinical features, coccidioidal 
pneumonia can be identiﬁ  ed only with appropriate labora-
tory studies.
C
occidioidomycosis is caused by infection with Coccid-
ioides spp., which consist of the nearly identical Coc-
cidioides immitis and C. posadasii that grow in the soils of 
the desert southwestern United States and in limited areas 
of Central and South America (1). When soil is disrupted, 
airborne arthroconidia can be inhaled, causing infections in 
humans and animals. These infections can be asymptom-
atic or can produce illness of varying severity, from mild, 
self-limited respiratory infection to severe, life-threatening 
pneumonia (2). In a small percentage of patients, Coccid-
ioides spp. may spread beyond the pulmonary tract, most 
frequently to the cutaneous, osteoarticular, or central ner-
vous systems (2).
The incidence of coccidioidomycosis has increased 
dramatically from 2.5 cases/100,000 persons in 1996 to 8.4 
cases/100,000 persons in 2006 in California (3) and from 
21 cases/100,000 in 1997 to 91 cases/100,000 in 2006 in 
Arizona (4). Clinicians in disease-endemic areas are usually 
aware of coccidioidomycosis but often do not consider the 
diagnosis in patients who initially have respiratory symp-
toms (5). A possible explanation for this oversight may be 
uncertainty about the frequency of coccidioidomycosis as 
a cause of acute community-acquired pneumonia (CAP). 
Valdivia et al. (5) reported that 29% of patients with CAP 
in Tucson, Arizona, had coccidioidomycosis. To determine 
the frequency of coccidioidal pneumonia in a second sam-
ple of the population, we studied patients with CAP in the 
Phoenix, Arizona, metropolitan area.
Methods
We evaluated patients with acute CAP who were ad-
mitted to our hospital or who sought care in the emergency 
department or ambulatory family practice and internal med-
icine outpatient clinics of our institution’s multispecialty 
referral practice and primary care practice in the Phoenix 
area. Patients were enrolled during February 2000–Novem-
ber 2004. This study was reviewed and approved by the 
Mayo Clinic Institutional Review Board.
Patients were eligible for enrollment if they had acute 
signs and symptoms of pneumonia (including but not lim-
ited to fever, cough, dyspnea, chills, and rash) and radio-
graphic evidence of a pulmonary inﬁ  ltrate identiﬁ  ed by 
an independent radiologist not on the study team. Patients 
were excluded if they were <18 years of age, were already 
receiving oral or parenteral antifungal treatment, had radio-
graphically documented pneumonia predating the current 
illness but within the past 3 months, were unable to return 
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for subsequent serologic tests, or were otherwise unwilling 
to provide informed consent. Patients were also excluded 
if the evaluating physician had initially suspected coccid-
ioidomycosis and had already ordered a serologic test for 
Coccidioides spp. as part of the initial clinical evaluation.
After goals and requirements of the study were ex-
plained to patients and informed consent was obtained, 
a pen-and-paper questionnaire was given to each patient 
for completion. The questionnaire collected information 
about patients’ residence in disease-endemic regions, oc-
cupations, daily activities, and previous medical condi-
tions. Within 24–48 hours of enrollment, participants had 
blood samples collected for serologic tests; these tests 
were repeated 6–8 weeks later. After all patients com-
pleted enrollment, we analyzed the patients’ clinical signs 
and symptoms and results of laboratory studies (includ-
ing serologic studies, complete blood cell counts, eryth-
rocyte sedimentation rates, eosinophil counts, and culture 
results, if obtained), chest radiographs, medical treatment, 
and follow-up data.
Serologic tests for Coccidioides  spp. were enzyme 
immunoassay (EIA), immunodiffusion (ID), and comple-
ment ﬁ  xation (CF) tests. Qualitative detection of immuno-
globulin (Ig) M and IgG to Coccidioides spp. by using EIA 
was performed by using a commercially available test kit 
(Meridian Bioscience, Inc., Cincinnati, OH, USA). ID and 
CF antibody tests were performed at the laboratory of Dr 
D. Pappagiannis (University of California Medical Center, 
Davis, CA, USA).
For this study, a case of coccidioidomycosis was de-
ﬁ  ned by the presence of acute signs or symptoms of re-
spiratory infection (e.g., cough, fever, pleuritic or chest 
pain, or dyspnea) in combination with a radiographically 
demonstrated pulmonary inﬁ  ltrate and positive results from 
paired (initial and follow-up) coccidioidal serologic tests. 
We considered results of paired serologic tests to be posi-
tive if we observed 1) seroconversion (an initial negative 
serologic result followed by a positive serologic result); 2) 
an initial positive serologic result followed by an increase 
in the number of positive qualitative test results among se-
rologic methods (e.g., initial EIA IgM positive, IgG nega-
tive, ID negative, CF negative followed by a positive result 
of >1 of the following: EIA IgG, ID, CF); or 3) an increase 
in serologic titer on the second CF test.
Differences in distributions of dichotomous variables 
were analyzed by using the χ2 test or the continuity-adjusted 
χ2 test when appropriate. The Fisher exact test was used for 
comparisons with small sample size. Differences between 
distributions of continuous variables were analyzed by us-
ing the independent t test. Data analysis was performed by 
using the statistical software program SAS version 9.1.3 
(SAS Institute, Inc., Cary, NC, USA).
Results
During February 2000–November 2004, 62 patients 
were enrolled in the study, 3 of whom were subsequently 
excluded from analysis because of incomplete question-
naires and lack of serologic results. Of the remaining 59 
patients, 35 completed the requirement for paired coccid-
ioidal serologic testing. For adequate statistical power, we 
wanted to enroll 175 patients. However, because of the 
slow accrual of patients, the study ended before we reached 
this target enrollment. Serologic results for the 59 study 
participants are summarized in Table 1.
All 35 patients who completed paired serologic testing 
were white, and 15 (43%) were men (Table 2). For 6 (17%) 
of the 35 patients (95% conﬁ  dence interval [CI] 7%–34%), 
a diagnosis of coccidioidomycosis was based on coccid-
ioidal antibody seroconversion. Patients with coccidioidal 
infection were more likely than those with noncoccidioi-
dal CAP to have rash (p = 0.002). Among 6 patients with 
coccidioidomycosis, no association was found between 
coccidioidal infection and patient’s sex or race, symptoms 
other than rash, ﬁ  ndings on chest radiographs, or laboratory 
data. Coccidioidal infection had no association with specif-
ic medical conditions, occupations, or recreational activi-
ties. Patients who had coccidioidomycosis had lived some-
what less time in the disease-endemic area (mean years of 
residency 14.6 years, range 2.5–26 years) than had patients 
whose pneumonia was caused by other factors (mean years 
of residency 25.2 years, range 0.5–69 years); this differ-
ence was not statistically signiﬁ  cant.
Of the original 59 patients enrolled, 24 were excluded 
because they lacked 1 of the 2 blood samples required for 
paired serologic testing. To ascertain whether bias was in-
troduced by this exclusion, we compared demographics, 
symptoms, and laboratory and radiographic ﬁ  ndings  of 
the excluded patients with those of the 35 patients who re-
mained in the study. The 24 excluded patients were more 
likely to have unilateral inﬁ  ltrates (22 [92%] of 24 vs 22 
[63%] of 35; p = 0.01). No other signiﬁ  cant differences 
were identiﬁ  ed.
Discussion
Pulmonary coccidioidomycosis is a febrile respiratory 
illness with symptoms similar to or identical to those of 
nonmycotic CAP. Common features include fever, head-
ache, cough, chest pain, dyspnea, and fatigue. This similar-
ity in symptoms makes it difﬁ  cult to recognize coccidioidal 
infection in the absence of diagnostic tests. Because most 
patients with primary coccidioidal pneumonia have sponta-
neous resolution of signs and symptoms, a patient with un-
diagnosed coccidioidomycosis who receives antibacterial 
therapy may appear to respond to treatment. However, a 
substantial portion of patients with coccidioidal pneumonia 
398  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 3, March 2009Coccidioidal Pneumonia, Phoenix, Arizona
may have a protracted course and may beneﬁ  t from spe-
ciﬁ  c antifungal treatment (6). Two of the authors (J.E.B. 
and J.D.S.) have observed that medical practitioners in the 
Phoenix metropolitan area often administer empiric anti-
bacterial treatment to patients with CAP and test for coc-
cidioidomycosis only when treatment fails (unpub. data). 
This combination of factors is likely to lead to underesti-
mation and underappreciation of the likelihood of coccid-
ioidomycosis as a cause of acute CAP.
 In the current study, we diagnosed coccidioidal infec-
tion in 6 (17%) of 35 (95% CI 7%–34%) patients in the 
Phoenix metropolitan area. Similarly, near Tucson, Ari-
zona, coccidioidomycosis had been identiﬁ  ed in 16 (29%) 
of 55 patients (95% CI 6%–44%) who sought treatment for 
CAP (5).The CIs associated with these incidence estimates 
overlap considerably. If we considered all enrolled patients 
in the current study who had >1 serologic test performed 
(similar to the methods of the previous study), a similar 
number of patients (10 [16.9%] of 59) had >1 positive re-
sult. Therefore, no clear differences between the 2 studies 
emerge, despite their differences in methods.
Because coccidioidal serologic tests may be insen-
sitive to early infection (7), we attempted to maximize 
identiﬁ  cation of coccidioidomycosis by requiring a sec-
ond specimen from the convalescent phase of the disease. 
Paired serologic testing was intended to eliminate the po-
tential for false-negative and false-positive results. Of the 
59 patients enrolled in our study, 3 had initial positive 
results for IgM by EIA but negative results for IgG by 
EIA and negative results by CF and ID. These 3 patients 
did not return for a second set of serologic tests; thus, 
their data (and those of several other patients who did not 
complete paired serologic testing for unknown reasons) 
were excluded from further analysis. The 3 patients posi-
tive for IgM by EIA but negative for IgG by EIA, CF, and 
ID may have had coccidioidomycosis. However, Crum et 
al. (8) reported that 18% of positive IgM EIA results with-
out other serologic corroboration may be false-positive 
results, whereas Blair and Currier found no false-positive 
results in a similar cohort (9). In the present study, the 
second serologic test resulted in subsequent diagnosis of 
coccidioidal infection in 6 patients for whom the infec-
tion had not been identiﬁ  ed by the initial serologic evalu-
ation. Although the requirement for paired serologic test-
ing made it exceedingly challenging to recruit participants 
and complete the study, the need for deﬁ  nitive serologic 
diagnosis was paramount.
At the time of the initial evaluation, we sought to 
identify and delineate signs and symptoms, laboratory 
ﬁ  ndings, and characteristics of patients that would help 
predict coccidioidal CAP. We conﬁ   rmed that rash, a 
symptom known to be associated with coccidioidal infec-
tion (8), was strongly suggestive of coccidioidal infection 
in patients with CAP. In contrast, Valdivia et al. (5) iden-
tiﬁ  ed myalgia as the only distinguishing clinical charac-
teristic. Perhaps because of the small number of patients 
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Table 1. Serologic test results for Coccidioides spp. in 59 patients, Phoenix, Arizona, USA, 2000–2004* 
First serologic result  Second serologic result 
No. patients  EIA IgM  EIA IgG  ID CF EIA IgM  EIA IgG  ID CF CF titer 
Negative serologic results: completed 2 tests 
 11  – – – – – – – –
 5  ND ND – – ND ND – –
 3  ND ND – – – – – –
 6  – – ND ND – – – –
 1  – – – – ND ND – –
 1  – – ND ND – – ND ND
 1  – – ND ND ND ND – –
 1  – – – – – – ND ND
Negative serologic results: completed 1 test 
 10  ND ND – – ND ND ND ND
 4  – – ND ND ND ND ND ND
 6  – – – – ND ND ND ND
Positive serologic results: completed 2 tests 
 2  – – – – + – + –
 1  ND ND – – + – + + 4
 1  ND ND – – – + – –
 1  ND ND – – – – + –
 1  – – – – – + + + 16
Positive serologic results: completed 1 test 
 3  + – – – ND ND ND ND
 1  ND ND ND ND – – – + 2
*EIA, enzyme immunoassay; Ig, immunoglobulin; ID, immunodiffusion; CF, complement fixation; ND, not done; –, negative test result; +, positive test 
result. RESEARCH
available for analysis in our study, we found that patterns 
on chest radiographs or other laboratory ﬁ  ndings did not 
enable us to differentiate between patients with and with-
out coccidioidal infection. There was no statistically sig-
niﬁ  cant association between coccidioidal infection and 
type of occupation or type of outdoor recreation activity. 
Likewise, we could not identify any statistically signiﬁ  -
cant association between coccidioidomycosis and number 
of years of residence in the disease-endemic area, as had 
been noted (10).
Several challenges limited enrollment of participants 
in this study. Most common was the issue of the second 
(or follow-up) serologic test. Many patients were initial-
ly willing to participate, but most were unable or unwill-
ing to return for a second serologic test and were thus not 
enrolled. Even among those who signed a consent form, 
completed a questionnaire, and provided an initial blood 
sample, the difﬁ  culty of returning for blood collection 6–8 
weeks later was shown by the large number of exclusions 
(24 of 59) because of a lack of paired samples. Soon after 
the study started, a second challenge arose among the pa-
tients whose physicians had already ordered serologic tests. 
In our institution, EIA results are reported within 1 day of 
test submission. Thus, a patient’s knowledge of this initial 
serologic result (whether positive or negative) often led to 
an unwillingness to participate. Ultimately, we revised the 
inclusion criteria.
Although a sizeable proportion of patients with CAP 
had coccidioidomycosis, we almost certainly underestimat-
ed its true frequency. We did not systematically attempt to 
isolate Coccidioides spp. from sputum or other respiratory 
specimens. Moreover, because the sensitivity of available 
coccidioidal serologic tests is <100%, some patients with 
coccidioidal CAP may not have been identiﬁ  ed. In addition, 
we did not enroll patients whose clinical evaluation had al-
ready included coccidioidal serologic testing. Despite these 
known preselection biases, we identiﬁ  ed coccidioidal in-
fection in 17% of persons with CAP for whom no suspicion 
of coccidioidomycosis was present initially. We speculate 
that this ﬁ  nding is an underestimate of the true percentage 
of coccidioidomycosis in patients with CAP. The limited 
value of currently available serologic tests makes the diag-
nosis of coccidioidomycosis difﬁ  cult, which will no doubt 
remain so until serologic tests are improved enough to de-
tect early infection.
Our identiﬁ  cation of coccidioidal infection in at least 1 
of 6 patients who sought treatment for radiologically con-
ﬁ  rmed CAP in an area where Coccidioides spp. are endemic 
underscores the likelihood that this infection is a common 
cause of CAP. We believe that coccidioidomycosis should 
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Table 2. Characteristics of 35 CAP patients with or without coccidioidomycosis, Phoenix, Arizona, USA, 2000–2004* 
No. patients 
Characteristic
With coccidioidomycosis 
(n = 6†) 
Without coccidioidomycosis 
(n = 29†)  p value 
Age, y, mean (range)  59.2 (38.0–80.3)  67.8 (61.8–73.8)  0.25
Male sex  2 (33)  13 (45)  0.60
White race  6 (100)  27 (93)  0.50
Location where evaluated 
  Hospital  4 (67)  20 (69)  0.99
  Emergency department  1 (17)  3 (10)  0.55
  Outpatient clinic  1 (17)  6 (21)  0.99
Signs and symptoms 
  Cough  4 (67)  27 (93)  0.12
  Sputum production  1 (17)  16 (55)  0.18
  Dyspnea  6 (100)  18 (62)  0.21
  Fever  5 (83)  21 (72)  0.99
  Chills  3 (50)  11 (38)  0.98
  Night sweats  2 (33)  7 (24)  0.99
 Rash  3  (50)  0 0.002
Chest radiograph findings 
  Unilateral infiltrates  5 (83)  17 (59)  0.50
  Bilateral infiltrates  1 (17)  8 (28)  0.96
Laboratory results 
  Leukocyte count, ×10
9 cells/L, mean (range)  15.1‡ (9.1–21.2)  11.0§ (9.1–12.9)  0.07
  Absolute eosinophil count, ×10
9 cells/L, mean (range)  2.96¶ (0.18–13)  0.12 (0.0–0.2)  0.32
Empiric coccidioidal treatment prescribed after initial visit  1 (17)  1 (3)  0.76
*CAP, community-acquired pneumonia. Values are no. (%) unless otherwise indicated. 
†Unless otherwise indicated. 
‡n = 6. 
§n = 25. 
¶n = 5. 
n = 22. Coccidioidal Pneumonia, Phoenix, Arizona
be strongly considered in the differential diagnosis of all 
patients with CAP who reside in, or who have recently vis-
ited, a disease-endemic area.
Ms Kim is a fourth-year medical student at the Kirksville 
College of Osteopathic Medicine in Kirksville, Missouri. Her re-
search interests are breast cancer, polycystic ovarian syndrome, 
and genetic variances in high-density lipoproteins. 
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